사이스파크(SPRC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $6.59 (-1.49%), 시가총액 $0.00B, PER 0.04, 52주 범위 $0.30 ~ $9.03.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical tri
사이스파크의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
사이스파크의 현재 주가는 $6.59 (-1.49%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
사이스파크의 시가총액은 약 $0.00B입니다. PER은 0.04입니다.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheime